Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

Lubiprostone

Unknown · small molecule · Diabetes Mellitus, Type 1

Lubiprostone for Diabetes Mellitus, Type 1 is a Unknown program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Unknown small molecule terminated

Internal code MCG 08-02-186

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Unknown
Modality
small_molecule
Indication
Diabetes Mellitus, Type 1
Status
terminated
Trials
1